CDNA

CareDx, Inc. (CDNA) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This summary covers the quarterly period ended June 30, 2025. CareDx, Inc. is a precision medicine company focused on diagnostic solutions for transplant patients, offering testing services (AlloSure, AlloMap), products (AlloSeq, Olerup SSP), and patient/digital solutions (Ottr, TransChart). The company operates primarily in the United States with facilities in California, Nebraska, and international operations in Sweden and Australia.

Key Financial Metrics

Note: Cash and Marketable Securities combined total $186.3 million as of June 30, 2025 ($68.2M cash + $118.0M marketable securities).

Material Changes vs. Prior Period

• Revenue Decline: Q2 2025 revenue decreased 6% year-over-year to $86.7 million. This was driven by a 13% decrease in testing services revenue ($62.0M vs $70.9M), primarily due to negative revenue adjustments of $3.8 million related to tests performed in prior periods. Excluding these adjustments, testing services revenue would have increased 14% due to a 13% increase in testing volume (49,500 tests).
• Product & Digital Growth: Product revenue increased 12% to $11.8 million, and Patient and Digital Solutions revenue increased 19% to $12.8 million, driven by higher sales of NGS-based kits and digital software (Ottr).
• Expense Management: General and Administrative (G&A) expenses decreased 10% to $27.7 million, largely due to a $5.6 million reduction in stock-based compensation. However, Sales and Marketing expenses increased 16% to $24.3 million.
• Litigation Impact: The company recorded a litigation settlement expense of $0.4 million in Q2 and $5.7 million for the six months ended June 30, 2025, related to a securities class action settlement.
• Share Repurchases: The company completed a $50.0 million share repurchase program in Q2, buying back 3.0 million shares. A new $50.0 million repurchase program was authorized in May 2025.

Guidance, Outlook, and Risks

• Liquidity: Management believes existing cash ($186.3 million) and expected cash from operations will be sufficient to meet requirements for the next 12 months. The company has no debt.
• Medicare Reimbursement Risk: A significant portion of revenue (36% for the six months) is derived from Medicare. The company faces uncertainty regarding the final reimbursement rate for a new CPT code (PLA Code 0540U) effective January 1, 2026, which could result in an $88 decrease per test for AlloSure Kidney.
• Internal Controls: The company disclosed a material weakness in internal control over financial reporting as of December 31, 2024, which remains unremediated as of June 30, 2025. This relates to insufficient risk assessment and control activities for complex transactions, specifically impacting stock-based compensation reporting.
• Litigation:
  • Securities Class Action: Settled in principle for approximately $20.25 million, with $14.9 million expected from insurance. Preliminary court approval was granted in July 2025.
  • Natera Litigation: Ongoing patent disputes. While a jury previously awarded Natera $96.3 million, a court later invalidated the patents in question. Natera has appealed, and the outcome remains uncertain.

Investor Verification Checklist

• Revenue Adjustments: Verify the impact of the $3.8 million negative revenue adjustment in Q2 and the methodology for future revenue recognition under ASC 606.
• Medicare Pricing: Monitor the final CMS pricing decision for PLA Code 0540U expected in late 2025, as this directly impacts future margins and revenue.
• Internal Control Remediation: Review the progress of the remediation plan for the material weakness in internal controls to ensure future financial reporting reliability.
• Litigation Finalization: Confirm the final court approval of the $20.25 million securities class action settlement and the status of the Natera patent appeal.
• Cash Burn: Assess the sustainability of the $16.7 million operating cash outflow over the last six months against the $186 million cash balance.